化疗改变前列腺癌和乳腺癌细胞的放射敏感性和GRPR表达
Tyrillshall S T Damiana1, Lilian van den Brink1, Lisette W de Kreij-de Bruin1
1Department of Radiology & Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
EJNMMI research
|August 2, 2025
概括
化疗显著影响前列腺癌和乳腺癌细胞中的胃素释放受体 (GRPR) 表达和治疗反应. 研究结果表明,化疗改变了GRPR介导的放射性核酸治疗的有效性,需要进一步的体外研究.
科学领域:
- 在瘤学瘤学.
- 放射性药物疗法是一种放射性药物疗法.
- 癌细胞生物学 癌细胞生物学
背景情况:
- 针对胃中释放受体 (GRPR) 的放射性追踪剂显示出癌症治疗的前景.
- 以前的化疗可以改变癌细胞特征,可能影响GRPR表达和治疗反应.
- 常见化疗对GRPR介导疗法的影响尚未完全理解.
研究的目的:
- 调查多克索鲁比辛 (DXR) 和多塞塔克塞尔 (DTX) 对GRPR表达,放射追踪剂吸收和对放射治疗的反应的影响.
- 在前列腺癌和乳腺癌模型中评估化疗前期治疗后,针对GRPR的放射性追踪剂的体内疗效.
主要方法:
- 用DXR或DTX治疗的前列腺癌 (PCa) 和乳腺癌 (BC) 细胞系的体外研究.
- 评估GRPR表达,辐射追踪器吸收和辐射敏感性.
- 在化疗后PC-3和T47D异种移植中[177Lu]Lu-NeoB吸收的体内SPECT/CT成像.
主要成果:
- 多塞 (DTX) 降低了PC-3细胞中的GRPR表达,放射性追踪剂吸收和放射敏感性.
- 多克索鲁比 (DXR) 增加了T47D细胞中的GRPR表达和放射性追踪剂的吸收,降低了它们对辐射的敏感性.
- 在体内实验室的研究显示,在化疗后,放射性追踪剂吸收的复杂变化,并不总是GRPR介导的.
结论:
- 化疗显著改变了GRPR介导的放射性核素治疗中的关键因素.
- 在体内发现的结果不那么明显,表明需要进一步研究来理解这些复杂的相互作用.
- 这些结果强调了在针对GRPR的治疗中考虑先前化疗的重要性.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Mitogens and the Cell Cycle
6.8K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
260
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
260


